{"id":107632,"date":"2024-03-06T05:43:08","date_gmt":"2024-03-06T05:43:08","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=120738"},"modified":"2024-03-06T05:43:08","modified_gmt":"2024-03-06T05:43:08","slug":"nyxoah-reports-fourth-quarter-and-financial-year-2023-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/jordannewsgazette.com\/nyxoah-reports-fourth-quarter-and-financial-year-2023-financial-and-operating-results\/","title":{"rendered":"Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results"},"content":{"rendered":"
\n

Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results<\/strong>
\nExpect to report DREAM U.S. pivotal study efficacy and safety data by early April<\/em>
\nAchieved record quarterly sales of \u20ac1.8 million<\/em><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 March 5, 2024 10:05pm CET \/ 4:05pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and financial year 2023.<\/p>\n

Recent Financial and Operating Highlights<\/strong><\/p>\n